ImmuCell Revenue 2006-2019 | ICCC
ImmuCell revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| ImmuCell Annual Revenue (Millions of US $) |
|
|---|---|
| 2018 | $11 |
| 2017 | $10 |
| 2016 | $10 |
| 2015 | $10 |
| 2014 | $8 |
| 2013 | $6 |
| 2012 | $5 |
| 2011 | $5 |
| 2010 | $4 |
| 2009 | $5 |
| 2008 | $5 |
| 2007 | $6 |
| 2006 | $5 |
| 2005 | $5 |
| ImmuCell Quarterly Revenue (Millions of US $) |
|
|---|---|
| Q3 2019 | $3 |
| Q2 2019 | $3 |
| Q1 2019 | $4 |
| Q4 2018 | $3 |
| Q3 2018 | $2 |
| Q2 2018 | $3 |
| Q1 2018 | $3 |
| Q4 2017 | $3 |
| Q3 2017 | $2 |
| Q2 2017 | $2 |
| Q1 2017 | $4 |
| Q4 2016 | $2 |
| Q3 2016 | $2 |
| Q2 2016 | $2 |
| Q1 2016 | $3 |
| Q4 2015 | $3 |
| Q3 2015 | $2 |
| Q2 2015 | $2 |
| Q1 2015 | $3 |
| Q4 2014 | $2 |
| Q3 2014 | $2 |
| Q2 2014 | $2 |
| Q1 2014 | $2 |
| Q4 2013 | $2 |
| Q3 2013 | $1 |
| Q2 2013 | $1 |
| Q1 2013 | $2 |
| Q4 2012 | $1 |
| Q3 2012 | $1 |
| Q2 2012 | $1 |
| Q1 2012 | $2 |
| Q4 2011 | $1 |
| Q3 2011 | $1 |
| Q2 2011 | $1 |
| Q1 2011 | $2 |
| Q4 2010 | $1 |
| Q3 2010 | $1 |
| Q2 2010 | $1 |
| Q1 2010 | $1 |
| Q4 2009 | $1 |
| Q3 2009 | $1 |
| Q2 2009 | $1 |
| Q1 2009 | $1 |
| Q4 2008 | $1 |
| Q3 2008 | $1 |
| Q2 2008 | $1 |
| Q1 2008 | $2 |
| Q4 2007 | $2 |
| Q3 2007 | $2 |
| Q2 2007 | $1 |
| Q1 2007 | $2 |
| Q4 2006 | $1 |
| Q3 2006 | $1 |
| Q2 2006 | $1 |
| Q1 2006 | $2 |
| Q4 2005 | $1 |
| Q3 2005 | $1 |
| Q2 2005 | $1 |
| Q1 2005 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.037B | $0.011B |
| ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $150.160B | 27.39 |
| Medtronic (MDT) | Ireland | $149.747B | 20.69 |
| Stryker (SYK) | United States | $74.065B | 24.90 |
| Boston Scientific (BSX) | United States | $61.077B | 28.83 |
| Baxter (BAX) | United States | $42.381B | 25.70 |
| Essilor Luxottica (ESLOY) | France | $33.712B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $30.238B | 18.97 |
| Terumo (TRUMY) | Japan | $26.963B | 33.65 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.222B | 0.00 |
| Coloplast (CLPBY) | Denmark | $24.840B | 38.33 |
| ResMed (RMD) | United States | $21.637B | 39.92 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $19.607B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $19.217B | 0.00 |
| Insulet (PODD) | United States | $11.140B | 529.97 |
| Bio-Rad Laboratories (BIO) | United States | $10.533B | 50.56 |
| DiaSorin S.p.A (DSRLF) | Italy | $7.616B | 0.00 |
| William Demant Holdings (WILYY) | Denmark | $7.531B | 0.00 |
| Perrigo (PRGO) | Ireland | $7.324B | 13.66 |
| Hill-Rom Holdings (HRC) | United States | $7.238B | 21.34 |
| Canopy Growth (CGC) | Canada | $7.058B | 0.00 |
| Haemonetics (HAE) | United States | $5.958B | 40.26 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $5.743B | 0.00 |
| GN STORE NORD (GNNDY) | Denmark | $5.276B | 27.26 |
| NuVasive (NUVA) | United States | $3.840B | 30.24 |
| ICU Medical (ICUI) | United States | $3.692B | 24.07 |
| Neogen (NEOG) | United States | $3.546B | 59.33 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.178B | 0.00 |
| Hutchison China MediTech (HCM) | Hong Kong, SAR China | $3.061B | 0.00 |
| Quidel (QDEL) | United States | $2.984B | 28.32 |
| Aurora Cannabis (ACB) | Canada | $2.669B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.596B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.423B | 54.70 |
| Cardiovascular Systems (CSII) | United States | $1.542B | 0.00 |
| InMode (INMD) | Israel | $1.364B | 0.00 |
| Aphria (APHA) | $1.230B | 0.00 | |
| AtriCure (ATRC) | United States | $1.218B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.182B | 23.68 |
| Phibro Animal Health (PAHC) | United States | $0.986B | 18.46 |
| NanoString Technologies (NSTG) | United States | $0.908B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.890B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.803B | 20.07 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.803B | 30.76 |
| Quanterix (QTRX) | United States | $0.704B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.697B | 39.17 |
| PetIQ (PETQ) | United States | $0.695B | 16.97 |
| Omeros (OMER) | United States | $0.662B | 0.00 |
| HEXO (HEXO) | $0.563B | 0.00 | |
| Cerus (CERS) | United States | $0.540B | 0.00 |
| Surmodics (SRDX) | United States | $0.532B | 55.32 |
| OraSure Technologies (OSUR) | United States | $0.485B | 29.07 |
| MacroGenics (MGNX) | United States | $0.474B | 0.00 |
| Owens & Minor (OMI) | United States | $0.445B | 16.47 |
| Organigram Holdings (OGI) | Canada | $0.400B | 0.00 |
| Meridian Bioscience (VIVO) | United States | $0.395B | 13.57 |
| Utah Medical Products (UTMD) | United States | $0.388B | 28.08 |
| BioLife Solutions (BLFS) | United States | $0.309B | 125.75 |
| Zynex (ZYXI) | United States | $0.293B | 33.19 |
| Bovie Medical (APYX) | United States | $0.273B | 0.00 |
| Neptune Wellness Solutions (NEPT) | Canada | $0.265B | 0.00 |
| United Health Products (UEEC) | United States | $0.245B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.244B | 25.76 |
| Vapotherm (VAPO) | United States | $0.244B | 0.00 |
| Repro-Med Systems (KRMD) | United States | $0.239B | 0.00 |
| Liberty Health Sciences (LHSIF) | Canada | $0.179B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.164B | 824.00 |
| Green Organic Dutchman Holdings (TGODF) | Canada | $0.160B | 0.00 |
| Female Health (VERU) | United States | $0.159B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.147B | 0.00 |
| MTech Acquisition (KERN) | United States | $0.132B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.129B | 0.00 |
| Fonar (FONR) | United States | $0.127B | 8.98 |
| Chimerix (CMRX) | United States | $0.116B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 22.91 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.076B | 0.00 |
| Nephros (NEPH) | United States | $0.066B | 0.00 |
| MRI Interventions (MRIC) | United States | $0.063B | 0.00 |
| Surface Oncology (SURF) | United States | $0.051B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.024B | 0.00 |
| Senestech (SNES) | United States | $0.016B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.015B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.014B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.013B | 0.00 |
| Myomo (MYO) | United States | $0.008B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.006B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.005B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.002B | 0.00 |
